Regulated Expression of CCL21 in the Prostate Tumor Microenvironment Inhibits Tumor Growth and Metastasis in an Orthotopic Model of Prostate Cancer

Overview

Journal Cancer Microenviron

Publisher Springer

Specialty Oncology

Date 2009 May 7

PMID 19418243

Citations 9

Authors

Nazita Yousefieh

Suzanne M Hahto

Amber L Stephens

Richard P Ciavarra

Affiliations

Soon will be listed here.

Abstract

Currently there are no curative therapies available for patients with metastatic prostate cancer. Thus, novel therapies are needed to treat this patient population. Immunotherapy represents one promising approach for the elimination of occult metastatic tumors. However, the prostate tumor microenvironment (TME) represents a hostile environment capable of suppressing anti-tumor immunity and effector cell function. In view of this immunosuppressive activity, we engineered murine prostate cancer cells with regulated expression (tet-on) of CCL21. Prostate tumor cells implanted orthotopically produced primary prostate tumors with predictable metastatic disease in draining lymph nodes and distant organs. Expression of CCL21 in the prostate TME enhanced survival, inhibited tumor growth and decreased the frequency of local (draining lymph node) and distant metastasis. Therefore, these studies provide a strong rationale for further evaluation of CCL21 in tumor immunity and its use in cancer immunotherapy.

Citing Articles

CXCR1 Expression in MDA-PCa-2b Cell Upregulates ITM2A to Inhibit Tumor Growth.

Adekoya T, Smith N, Kothari P, Dacanay M, Li Y, Richardson R Cancers (Basel). 2025; 16(24.

PMID: 39766038 PMC: 11674668. DOI: 10.3390/cancers16244138.

Endogenous CCL21-Ser deficiency reduces B16-F10 melanoma growth by enhanced antitumor immunity.

Fujie R, Kurowarabe K, Yamada Y, Fujiwara K, Nakatani H, Tsutsumi K Heliyon. 2023; 9(8):e19215.

PMID: 37664721 PMC: 10469598. DOI: 10.1016/j.heliyon.2023.e19215.

Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.

Chen Q, Yin H, Pu N, Zhang J, Zhao G, Lou W Cancer Sci. 2021; 112(11):4457-4469.

PMID: 34402138 PMC: 8586683. DOI: 10.1111/cas.15110.

Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.

Poelaert B, Romanova S, Knoche S, Olson M, Sliker B, Smits K J Control Release. 2020; 327:266-283.

PMID: 32711026 PMC: 7606783. DOI: 10.1016/j.jconrel.2020.07.024.

IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalis promotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages.

Han I, Song H, Ryu J PLoS Negl Trop Dis. 2020; 14(3):e0008126.

PMID: 32196489 PMC: 7138318. DOI: 10.1371/journal.pntd.0008126.

References

Fan L, Reilly C, Luo Y, Dorf M, Lo D . Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol. 2001; 164(8):3955-9. DOI: 10.4049/jimmunol.164.8.3955. View

Liang C, Zhong C, Sun R, Liu B, Huang C, Qin J . Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol. 2007; 81(17):9502-11. PMC: 1951415. DOI: 10.1128/JVI.00208-07. View

Sharma S, Stolina M, Luo J, Strieter R, Burdick M, Zhu L . Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000; 164(9):4558-63. DOI: 10.4049/jimmunol.164.9.4558. View

Vicari A, Chemin K, Mueller A, Zlotnik A, Caux C . Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000; 165(4):1992-2000. DOI: 10.4049/jimmunol.165.4.1992. View

Ciavarra R, Holterman D, Brown R, Mangiotti P, Yousefieh N, Wright Jr G . Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother. 2003; 27(1):13-26. DOI: 10.1097/00002371-200401000-00002. View

Arenberg D, Zlotnick A, Strom S, Burdick M, Strieter R . The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother. 2001; 49(11):587-92. PMC: 11037015. DOI: 10.1007/s002620000147. View

den Haan J, Lehar S, Bevan M . CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 2000; 192(12):1685-96. PMC: 2213493. DOI: 10.1084/jem.192.12.1685. View

Kwon E, Foster B, Hurwitz A, Madias C, Allison J, Greenberg N . Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A. 1999; 96(26):15074-9. PMC: 24775. DOI: 10.1073/pnas.96.26.15074. View

Warnock R, Campbell J, Dorf M, Matsuzawa A, McEvoy L, Butcher E . The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med. 2000; 191(1):77-88. PMC: 2195795. DOI: 10.1084/jem.191.1.77. View

10.

Kirk C, Nickoloff B, Chamberlain J, Giedlin M, Aukerman L, Mule J . T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001; 61(5):2062-70. View

11.

Gunn M, Tangemann K, Tam C, Cyster J, Rosen S, Williams L . A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A. 1998; 95(1):258-63. PMC: 18193. DOI: 10.1073/pnas.95.1.258. View

12.

Somers K, Brown R, Holterman D, Yousefieh N, Glass W, Wright Jr G . Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer. 2003; 107(5):773-80. DOI: 10.1002/ijc.11464. View

13.

Chikazawa M, Inoue K, Fukata S, Karashima T, Shuin T . Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology. 2008; 75(6):335-45. DOI: 10.1159/000164218. View

14.

Foster B, Gingrich J, Kwon E, Madias C, Greenberg N . Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997; 57(16):3325-30. View

15.

Willimann K, Legler D, Loetscher M, Roos R, Delgado M, Clark-Lewis I . The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol. 1998; 28(6):2025-34. DOI: 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C. View

16.

Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M . Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2001; 61(17):6406-12. View

17.

Schmielau J, Finn O . Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001; 61(12):4756-60. View

18.

Ciavarra R, Brown R, Holterman D, Garrett M, Glass 2nd W, Wright Jr G . Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother. 2003; 52(9):535-45. PMC: 11034273. DOI: 10.1007/s00262-003-0383-x. View

19.

Gabrilovich D, Velders M, Sotomayor E, Kast W . Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001; 166(9):5398-406. DOI: 10.4049/jimmunol.166.9.5398. View

20.

Koizumi K, Kozawa Y, Ohashi Y, Nakamura E, Aozuka Y, Sakurai H . CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro. Oncol Rep. 2007; 17(6):1511-6. View